You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mitogen-Activated Protein Kinase Kinase inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Shanghai, China
  • +1 more
Jan 13, 2023

Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)

Active, not recruiting
  • Neurofibromatosis 1
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

Neurofibromatosis Type 1 Trial in Japan (Selumetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Minato-ku, Japan
  • +3 more
Jun 9, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Tumor, Solid, Gastrointestinal Cancer Trial in San Francisco, Ann Arbor (Ulixertinib, Hydroxychloroquine)

Recruiting
  • Tumor, Solid
  • Gastrointestinal Cancer
  • Tucson, Arizona
  • +7 more
Jan 13, 2023

Cancer Trial in Changsha (Protein Kinase Inhibitor)

Recruiting
  • Cancer
  • Protein Kinase Inhibitor
  • Changsha, Hunan, China
    Central South University
Jun 23, 2022

Advanced Cancer, Metastatic Cancer, Solid Tumor Trial in United States (JZP815)

Recruiting
  • Advanced Cancer
  • +2 more
  • Denver, Colorado
  • +4 more
Jan 10, 2023

Rechallenge of BRAF +/- MEK Inhibitors FollowingAdverse Event in

Active, not recruiting
  • Cancer
  • BRAF inhibitor
  • (no location specified)
Oct 13, 2021

Acute Myeloid Leukemia Trial in United States (ERAS-007, ERAS-601, Gilteritinib)

Withdrawn
  • Acute Myeloid Leukemia
  • San Francisco, California
  • +3 more
Jun 13, 2022

Hepatocellular Carcinoma Trial in Taichung (Xiang Sha Liu Jun Zi Decoction dry powder, XSLJZ Placebo)

Enrolling by invitation
  • Hepatocellular Carcinoma
  • Xiang Sha Liu Jun Zi Decoction dry powder
  • XSLJZ Placebo
  • Taichung, 西屯區, Taiwan
    China Medical University hospital
Dec 9, 2021

Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency Trial in Providence (Palbociclib Oral

Not yet recruiting
  • Advanced Breast Cancer
  • +6 more
  • Providence, Rhode Island
    Lifespan Cancer Institute
Feb 1, 2023

Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma Trial in Worldwide (Binimetinib Oral Tablet

Not yet recruiting
  • Adamantinous Craniopharyngioma
  • Recurrent Adamantinomatous Craniopharyngioma
  • Binimetinib Oral Tablet [Mektovi]
  • Aurora, Colorado
  • +17 more
Nov 28, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor Trial in United States (CDK Inhibitor

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • CDK Inhibitor AT7519
  • +3 more
  • Washington, District of Columbia
  • +5 more
Oct 18, 2022

Advanced Solid Tumors With MAPK Pathway Mutations Trial in Nedlands (D3S-002)

Not yet recruiting
  • Advanced Solid Tumors With MAPK Pathway Mutations
  • Nedlands, Western Australia, Australia
    D3 Bio Investigative Site
May 24, 2023

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Lung Cancer Trial in Carlsbad, Cleveland (ISIS 3521, carboplatin, paclitaxel)

Completed
  • Lung Cancer
  • ISIS 3521
  • +2 more
  • Carlsbad, California
  • +1 more
Dec 1, 2022

Uveal Melanoma Trial in New York, Houston (Selumetinib)

Active, not recruiting
  • Uveal Melanoma
  • New York, New York
  • +2 more
Jun 28, 2022

Resistance-associated Mutations in Metastatic Lung Cancer

Recruiting
  • Lung Cancer
  • Liquid biopsy
  • Monza, MB, Italy
    Fondazione IRCCS San Gerardo dei Tintori
Oct 10, 2023

Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

COVID-19 Trial in Worldwide (Losmapimod oral tablet, Placebo oral tablet)

Terminated
  • COVID-19
  • Losmapimod oral tablet
  • Placebo oral tablet
  • Irvine, California
  • +15 more
Mar 30, 2022

Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial

Not yet recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • +3 more
  • Biopsy
  • +8 more
  • (no location specified)
Jan 13, 2023

Uveal Melanoma Trial in Worldwide (LXS196, LXS196 and HDM201)

Terminated
  • Uveal Melanoma
  • New York, New York
  • +5 more
Sep 27, 2022

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma

Active, not recruiting
  • Melanoma
  • Dabrafenib and Trametinib
  • Buxtehude, Niedersachsen, Germany
  • +35 more
Aug 25, 2022

Low-grade Glioma, Plexiform Neurofibroma, CNS Glioma Trial in Canada (Trametinib)

Active, not recruiting
  • Low-grade Glioma
  • +2 more
  • Calgary, Alberta, Canada
  • +6 more
Oct 25, 2022